ZYMEWORKS INC. - COMMON STOCK

26,61

01-мая-26 16:45:00

15 мин. задержка

Акции

-0,93

-3,38%

Сегодняшний диапазон

26,61 - 27,54

ISIN

N/A

Источник

NASDAQ

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

12 янв 2026 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026

11 янв 2026 18:00:00 Источник Nasdaq GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

06 янв 2026 13:34:22 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Conferences

02 дек 2025 16:05:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

24 ноя 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

18 ноя 2025 01:01:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

18 ноя 2025 01:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

17 ноя 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

06 ноя 2025 16:05:03 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

28 окт 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

23 окт 2025 12:30:00 Источник Nasdaq GlobeNewswire
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

16 окт 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

13 окт 2025 16:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

09 окт 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

02 сен 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences

19 авг 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

11 авг 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

07 авг 2025 16:05:03 Источник Nasdaq GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

28 июл 2025 06:00:00 Источник Nasdaq GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

17 июл 2025 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.